APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US11274140B2 · kind B2 · utility
2Cited by
43References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2021 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Jun 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.